Introduction
============

Atrial fibrillation (AF) is increasing in prevalence and is associated with significant morbidity and mortality.^[@b1]^ Large genome‐wide association studies (GWAS) have identified novel genetic loci related to AF and PR interval. To date, 11 AF‐associated, single nucleotide polymorphisms (SNPs) have been identified and replicated.^[@b2]--[@b7]^ Furthermore, left atrial size has been related to the occurrence of incident AF and recurrence following radiofrequency catheter ablation.^[@b8]--[@b9]^ Whether SNPs associated with AF are related to LA size or dimensions has had limited investigation. We therefore hypothesized that SNPs related to AF would be associated with measures of atrial structure, an AF intermediate phenotype. We specifically examined the relations between each SNP and left atrial (LA) dimension, as determined by transthoracic echocardiography, and LA volume, as determined by cardiovascular magnetic resonance (CMR). Demonstrating such an association would suggest that genetic associations related to AF may also play a role in atrial structure.

Methods
=======

Study Sample
------------

The Framingham Heart Study is a prospective, community‐based investigation of the epidemiology of cardiovascular disease. In brief, the Study began in 1948 by enrolling the Original Cohort, followed by the children of the Original Cohort and their spouses in 1971, known as the Offspring Cohort.^[@b10]^ In turn, children of the Offspring Cohort were enrolled in 2002 as the Third Generation Cohort.^[@b11]^ Participants have undergone routine examinations every 2 to 8 years since enrollment including extensive phenotyping with periodic noninvasive cardiovascular imaging studies and comprehensive genotyping. The present analysis included participants who attended Offspring Cohort examination 6 (n=3532), examination 7 (n=3539), and the Third Generation\'s first examination (n=4095). The study was approved by the Boston University Medical Center Institutional Review Board, and all participants provided written informed consent.

Echocardiography
----------------

Participants in Offspring examination 6 (1995--1998) and Third Generation examination 1 (2002--2005) underwent transthoracic echocardiography employing a standardized protocol. Echocardiography in the Framingham Heart Study has been well described and was performed using a Hewlett‐Packard Sonos 1000 in the Offspring Cohort and Hewlett‐Packard Sonos 5500 in the Third Generation Cohort (Hewlett‐Packard Medical Products) by certified sonographers and over‐read by technicians and cardiologists.^[@b12]--[@b13]^ LA diameter measurement was conducted according to guidelines from the American Society of Echocardiography^[@b14]^ and entailed M‐mode measurement recorded at end‐systole in the parasternal long‐ or short‐axis views. The maximum distance from the wall of the posterior aortic root to the posterior LA was measured in up to 4 cycles for each participant. Prior analyses have described excellent inter‐ and intra‐rater reproducibility for Framingham Heart Study LA diameter measurement using this approach.^[@b15]^ In total, 6861 Framingham Heart Study participants underwent echocardiography at the examinations relevant to this analysis. Left ventricular mass and fractional shortening also were calculated as described previously.^[@b12]^ All echocardiography reading was done offline by readers who were blinded to participant clinical characteristics.

Cardiovascular Magnetic Resonance
---------------------------------

A subset of participants in the Offspring examination 7 (1998--2001) was included in a study using noncontrast CMR. Exclusions for CMR included any identified contraindication to CMR (eg, defibrillator or pacemaker implantation) or severe claustrophobia. Participants underwent imaging in the supine position in a 1.5 Tesla MRI scanner (Gyroscan NT; Philips Healthcare). After scout images to determine the position and orientation of the heart within the thorax an electrocardiogram‐gated, steady‐state free precession cine sequence was acquired in the anatomic 2‐chamber and 4‐chamber orientations. Imaging measures included TR=3.2 ms, TE=1.6 ms, flip angle=60°, slice thickness=10 mm with 1.9×1.6‐mm^2^ in‐plane spatial resolution. Images were processed off‐line using commercially available software (MASS v.6.1; QT‐Medis) by a single observer (GA). In each view, the systolic frame immediately prior to mitral valve opening was identified and the cross‐sectional area of the LA was manually planimetered. Particular care was taken to exclude left atrial appendage and pulmonary vein ostia from left atrial area. Left atrial volume was then calculated using the biplane formula: =8×A~2c~×A~4c~/(3πL~min~) for which A~2c~ and A~4c~ are the planimetered areas and L~min~ is the minimum of the 2‐chamber and 4‐chamber LA lengths. In total, 1810 participants from the Offspring Cohort underwent CMR using a standardized protocol.^[@b16]^ All readers were blinded to participant identity and clinical characteristics.

Genotyping and SNP Selection
----------------------------

Genotyping of Framingham Heart Study participants has been described elsewhere.^[@b17]^ In the present study, SNPs were selected from their established association with AF in large GWAS including Framingham Heart Study Offspring and Original Cohort participants.^[@b2]--[@b7]^ Only SNPs that had reached statistical significance in GWAS meta‐analyses after application of Bonferroni correction (*P*\<5.0×10^−8^) were included in the present analysis.

Covariates
----------

Covariates were selected for their established associations with AF in the Framingham Heart Study and other cohorts, and for their potential relation to longitudinal modification of atrial structure.^[@b13],[@b18]--[@b19]^ Covariates selected for inclusion were age, sex, body mass index, systolic blood pressure, treatment for hypertension, valvular heart disease, and prevalent cardiovascular disease and heart failure. Participants with prevalent AF, ie, a history of documented AF according to Framingham Heart Study criteria that were present at or prior to the imaging assessment, were included in our primary analysis. The Framingham Heart Study protocol for adjudicating AF has been described elsewhere.^[@b19]^

Statistical Analyses
--------------------

We examined the distributions of continuous variables (means, standard deviations, summaries). We examined correlations between clinical characteristics and cardiac imaging measures using the Pearson product‐moment correlation coefficient. For CMR analysis we employed linear mixed models to determine the associations between selected SNPs and measures of LA volume with a random effect to account for sibling correlation. For echo analysis considering that the sample was composed of 2 generations, we used generalized estimating equations to obtain robust standard errors in evaluating the association between SNPs and LA dimension. All correlation and regression models were adjusted for age and sex. We conducted a primary analysis including participants with prevalent AF, and a secondary analysis that excluded participants with prevalent AF. We conducted a post hoc power calculation using the method described by Cohen.^[@b20]^ All analyses were performed using SAS version 9.2 (SAS Institute). A *P* value \<0.0023 (0.05 with 11 SNPs and 2 LA phenotypes) was deemed statistically significant to account for multiple testing.

Results
=======

The study sample for the examination of selected SNPs and LA measures consisted of 6861 participants with echocardiographic LA dimension and 1555 participants with CMR LA volume. The LA imaging measures were considered as separate assessments in relation to the selected AF SNPs. In total 1465 participants had both CMR and echocardiography, 90 CMR only, and 5396 echocardiography only. We analyzed them separately because they were done at different time points and with different technology.

The characteristics of the study samples and the distribution of LA measures are described in Table[1](#tbl01){ref-type="table"}. The sample with echocardiographic LA dimension was larger and younger than the CMR LA volume sample, reflecting the contribution of the younger Third Generation Cohort and earlier examination of the Offspring Cohort. Mean left ventricular mass differed between echocardiographic and CMR assessments. The mean LA volume by CMR was 73.5±23.8 mL. Echocardiographic LA volume was not determined. The number of participants with prevalent AF was limited (5.0% of the CMR cohort and 1.5% of the echocardiography cohort).

###### 

Clinical Characteristics of the Framingham Heart Study Samples According to Cardiac Imaging Modality

                                        CMR (n=1555)   Echocardiography (n=6861)
  ------------------------------------- -------------- ---------------------------
  Clinical characteristics                             
  Age, y                                60±9           48±13
  Women, %                              827 (53)       3626 (52)
  Body mass index, kg/m^2^              27.8±4.8       27.3±5.3
  Body surface area, m^2^               1.90±0.23      1.91±0.25
  Systolic blood pressure, mm Hg        125±18         122±17
  Hypertension treatment, %             450 (29)       1144 (17)
  Prevalent cardiovascular disease, %   93 (6.0)       186 (2.7)
  Prevalent atrial fibrillation, %      77 (5.0)       104 (1.5)
  Valvular heart disease, %             31 (2.0)       124 (1.8)
  Imaging                                              
  LV ejection fraction, %               67±7           ---
  LV mass, g                            106±30         159±43
  LA volume, mL                         73.5±23.8      ---
  LA dimension, mm                      ---            38.2±5.3
  LV fractional shortening              ---            0.36±0.05

Continuous measures provided as means±SD and categorical as N (%). CMR indicates cardiovascular magnetic resonance; LA, left atrium; LV, left ventricular.

Table[2](#tbl02){ref-type="table"} describes correlations between the clinical characteristics and the imaging measures. The correlation between LA volume and LA diameter was moderate (*r*=0.41, *P*\<0.001). We observed a significant correlation (*r*=0.33, *P*\<0.001) between LA volume and left ventricular mass as measured by CMR. We also found significant, modest associations between both LA volume and LA dimension with prevalent AF.

###### 

Age‐ and Sex‐Adjusted Correlations (r) Between Selected Clinical and Imaging Variables in the Framingham Heart Study

                                     Cardiovascular Magnetic Resonance LA Volume (mL)   Echocardiography LA Dimension (mm)
  ---------------------------------- -------------------------------------------------- ------------------------------------
  Body mass index, kg/m^2^           0.17^\*^                                           0.45^\*^
  Systolic blood pressure, mm Hg     0.08^†^                                            0.14^\*^
  Hypertension treatment             0.13^\*^                                           0.18^\*^
  Prevalent cardiovascular disease   0.13^\*^                                           0.10^\*^
  Prevalent atrial fibrillation      0.21^\*^                                           0.14^\*^
  LV ejection fraction, %^‡^         −0.03                                              −0.03
  LV mass, g                         0.33^\*^                                           0.60^\*^
  LA diameter, mm                    0.41^\*^                                           ---

LA indicates left atrium; LV, left ventricular.

\**P*\<0.001. ^†^*P*\<0.05. ^‡^Refers to fractional shortening for echocardiography assessment.

The associations between the relevant SNPs and the LA measures are shown in Table[3](#tbl03){ref-type="table"}. Two SNPs were associated with CMR LA volume as determined by CMR. Both SNPs were in proximity to the *PITX2* gene, which regulates cardiac development and atrial electrical function.^[@b21]^ When we adjusted for body surface area, the associations between these 2 SNPs and LA volume were no longer significant.

###### 

Age‐ and Sex‐Adjusted Associations Between AF SNPs and LA Measures

               SNP   Cardiovascular Magnetic Resonance   Echocardiography                                                         
  ------------ ----- ----------------------------------- ------------------ ------------ ------ ------------ ------ ------------- ------
  rs2200733    4     T                                   *PITX2*            −2.52±1.19   0.04   −0.86±0.60   0.15   0.10±0.12     0.41
  rs17570669   4     T                                   *PITX2*            −4.49±1.88   0.02   −1.59±0.94   0.09   −0.09±0.18    0.59
  rs3853445    4     C                                   *PITX2*            −1.12±0.90   0.18   −0.51±0.45   0.26   −0.06±0.09    0.51
  rs13376333   1     T                                   *KCNN3*            0.95±1.02    0.35   0.45±0.51    0.38   −0.05±0.10    0.62
  rs2106261    16    T                                   *ZFHX3*            −0.41±1.14   0.72   −0.51±0.57   0.37   −0.21±0.11    0.06
  rs6666258    1     C                                   *KCNN3*            0.95±1.02    0.35   0.45±0.52    0.38   −0.05±0.10    0.62
  rs3807989    7     A                                   *CAV1*             0.29±0.84    0.73   0.33±0.42    0.42   −0.08±0.08    0.35
  rs10821415   9     A                                   *C9orf3*           −0.58±0.82   0.48   −0.22±0.41   0.56   −0.10±0.11    0.38
  rs10824026   10    G                                   *SYNPO2L*          0.00±1.09    0.99   0.06±0.55    0.91   −0.002±0.08   0.98
  rs1152591    14    A                                   *SYNE2*            0.68±0.82    0.41   0.49±0.42    0.24   0.05±0.09     0.57
  rs7164883    15    G                                   *HCN4*             0.52±1.07    0.63   0.14±0.54    0.80   −0.12±0.11    0.28

All analyses age‐ and sex‐adjusted, and echocardiography results further adjusted for cohort. AF indicates atrial fibrillation; BSA, body surface area; Chr, chromosome; LA, left atrium; SNP, single nucleotide polymorphism.

All coded alleles are minor alleles and refer to the allele associated with AF risk as identified in genome‐wide association studies referenced in text.

In secondary analyses we excluded participants with prevalent AF (n=77 in the CMR sample and n=105 in the echocardiography sample). Results of the secondary analysis are reported in Table[4](#tbl04){ref-type="table"}. The statistical association between 2 of the *PITX2* SNPs and LA volume as measured by CMR were nominally significant, but none of the findings met our threshold for statistical significance. A single SNP (rs2200733) in proximity to *PITX2* was associated (β=−1.22±0.60, *P*=0.04) with LA volume following adjustment for body surface area. A second SNP (rs2106261) in proximity to the *ZFHX3* gene was related (β=−0.22±0.11, *P*=0.04) to LA diameter. We were further concerned about potential misclassification of atrial structure by including individuals with valvular heart disease. Therefore, we conducted an analysis excluding the ≈2% of individuals with valvular heart disease; the results were not substantively affected (Table[5](#tbl05){ref-type="table"}).

###### 

Age‐ and Sex‐Adjusted Associations Between AF SNPs and LA Measures, Excluding Prevalent AF

               SNP   Cardiovascular Magnetic Resonance   Echocardiography                                                        
  ------------ ----- ----------------------------------- ------------------ ------------ ------ ------------ ------ ------------ ------
  rs2200733    4     T                                   *PITX2*            −3.15±1.18   0.01   −1.22±0.60   0.05   0.03±0.11    0.80
  rs17570669   4     T                                   *PITX2*            −4.63±1.81   0.01   −1.74±0.92   0.06   −0.05±0.18   0.78
  rs3853445    4     C                                   *PITX2*            −1.13±0.89   0.20   −0.47±0.45   0.30   −0.03±0.09   0.75
  rs13376333   1     T                                   *KCNN3*            0.58±1.00    0.56   0.31±0.51    0.55   −0.04±0.09   0.66
  rs2106261    16    T                                   *ZFHX3*            −0.91±1.12   0.42   −0.77±0.57   0.18   −0.22±0.11   0.04
  rs6666258    1     C                                   *KCNN3*            0.58±1.00    0.56   0.31±0.51    0.55   −0.04±0.09   0.66
  rs3807989    7     A                                   *CAV1*             0.04±0.83    0.96   0.15±0.42    0.73   0.01±0.08    0.91
  rs10821415   9     A                                   *C9orf3*           −1.03±0.81   0.21   −0.36±0.41   0.38   −0.04±0.09   0.66
  rs10824026   10    G                                   *SYNPO2L*          1.47±1.07    0.17   0.72±0.55    0.19   −0.08±0.11   0.48
  rs1152591    14    A                                   *SYNE2*            0.61±0.81    0.45   0.31±0.41    0.46   0.06±0.08    0.44
  rs7164883    15    G                                   *HCN4*             1.18±1.05    0.27   0.50±0.54    0.35   −0.02±0.11   0.87

All analyses age‐ and sex‐adjusted, and echocardiography results further adjusted for cohort. AF indicates atrial fibrillation; BSA, body surface area; Chr, chromosome; LA, left atrium; SNP, single nucleotide polymorphism.

All coded alleles are minor alleles and refer to the allele associated with AF risk as identified in genome‐wide association studies referenced in text.

###### 

Age‐ and Sex‐Adjusted Associations Between AF SNPs and LA Measures, Excluding Prevalent AF and VHD

               SNP   Cardiovascular Magnetic Resonance   Echocardiography                                                          
  ------------ ----- ----------------------------------- ------------------ ------------ ------ -------------- ------ ------------ ------
  rs2200733    4     T                                   *PITX2*            −2.81±1.16   0.02   −1.08±0.60     0.07   0.03±0.11    0.78
  rs17570669   4     T                                   *PITX2*            −4.64±1.79   0.01   −1.86±0.92     0.04   0.01±0.18    0.96
  rs3853445    4     C                                   *PITX2*            −1.15±0.88   0.19   −0.55±0.45     0.22   −0.01±0.09   0.92
  rs13376333   1     T                                   *KCNN3*            0.87±0.99    0.38   0.43±0.51      0.40   −0.02±0.10   0.80
  rs2106261    16    T                                   *ZFHX3*            −1.56±1.10   0.16   −0.1.05±0.56   0.06   −0.25±0.11   0.02
  rs6666258    1     C                                   *KCNN3*            0.87±0.99    0.38   0.43±0.51      0.40   −0.02±0.10   0.80
  rs3807989    7     A                                   *CAV1*             0.38±0.81    0.65   0.32±0.42      0.44   0.04±0.08    0.64
  rs10821415   9     A                                   *C9orf3*           −1.01±0.80   0.65   −0.38±0.41     0.36   0.05±0.09    0.54
  rs10824026   10    G                                   *SYNPO2L*          0.91±1.05    0.39   0.53±0.54      0.33   −0.08±0.11   0.45
  rs1152591    14    A                                   *SYNE2*            0.72±0.80    0.37   0.38±0.41      0.36   0.09±0.08    0.27
  rs7164883    15    G                                   *HCN4*             1.27±1.04    0.22   0.58±0.54      0.28   −0.05±0.11   0.64

All analyses age‐ and sex‐adjusted, and echocardiography results further adjusted for cohort. AF indicates atrial fibrillation; BSA, body surface area; Chr, chromosome; LA, left atrium; SNP, single nucleotide polymorphism; VHD, valvular heart disease.

All coded alleles are minor alleles and refer to the allele associated with AF risk as identified in genome‐wide association studies referenced in text.

In view of our negative findings, we conducted a post‐hoc power calculation. Among the 11 SNPs, rs2200733 had the smallest *P* value in association with LA volume (*P*=0.02), explaining 0.23% of residual variability in LA volume. Given the limited‐sized sample (n=1555), we had only 14% statistical power to detect such an effect size at alpha=0.0023 level. With this sample size, we would have 40% and 60% power to detect a SNP explaining 0.50% and 0.69% variability in LA volume, respectively. Rs2106261 had the smallest *P* value in association with LA diameter as determined by echocardiography (*P*=0.06), explaining 0.10% of the residual variability in LA diameter. Given the sample size (n=6861), we had 38% power to detect such an effect size at alpha=0.0023 level. We would have 50% and 70% power to detect a SNP explaining 0.14% and 0.19% variability in LA dimension, respectively.

Discussion
==========

We hypothesized that selected SNPs, identified from large GWAS for AF, are associated with measures of atrial structure determined by noninvasive cardiac imaging in a community‐based cohort. Our hypothesis was informed by animal and human electrophysiologic studies and further consideration of genetic contributions to atrial electrical and structural remodeling. As atrial structure serves as an intermediate phenotype for AF and is directly related to risk,^[@b8],[@b22]^ we postulate that AF genetic variants mediated atrial structural remodeling. However, our analysis did not identify a significant association between the genetic loci and atrial structures.

The AF SNPs examined in our analysis were selected from GWAS. Specifically, 3 of the SNPs studied here (rs2200733, rs17570669, and rs3853445) are on chromosome 4q25 and are located upstream of the *PITX2* gene, which is relevant for atrial tissue development. *PITX2c*‐deficient mice do not develop pulmonary myocardial cells or pulmonary myocardial sleeves.^[@b23]^ The *PITX2c* isoform impedes LA sinus node development.^[@b24]^ *PITX2c* −/− increases vulnerability to atrial arrhythmias.^[@b25]^ In studies of human atrial tissue, *PITX2* expression levels are ≈2 orders of magnitude higher in the LA compared to the right atrium or the ventricles.^[@b26]^ Finally, *PITX2c* heterozygote mice were susceptible to AF induced by pacing and had shorter atrial action potential durations compared with the wild type controls.^[@b27]^ Our study did not identify an association between the 4q25 SNPs and measures of atrial structure. Further studies of the AF‐associated SNPs, *PITX2* and expression are essential to determine their relevance towards atrial structure and function.

Many of the other AF‐risk SNPs do not have a clear relation to cardiac development or atrial structure. SNP rs13376333 is intronic to *KCNN3*, a gene that encodes a calcium‐activated potassium channel.^[@b4]^ SNP rs2106261 is found in a zinc finger homeobox transcription factor, *ZFHX3*, which participates in myogenic and neuronal differentiation. The association of this SNP with AF has been replicated in an Asian cohort and associated with coronary disease in an African American cohort.^[@b27]--[@b28]^ SNP rs3807989 is intronic to *CAV1*, and has been associated with AF and the PR and QRS intervals.^[@b29]--[@b30],[@b17]^

We considered that individuals with genetic polymorphisms making them susceptible to AF may experience altered LA structure.^[@b8]^ However, all the 11 AF SNPs we examined were not significantly associated with LA volume and dimension in our samples. Further work with a larger sample and longitudinal measures of LA structure may discern if there is a genetic contribution towards atrial structure and remodeling.

We are not aware of other literature examining SNPs related to AF and measures of LA structure. A large (n=12 612) GWAS investigating genetic variants associated with echocardiographic traits did not identify genetic loci associated with LA size.^[@b31]^ Comparison between these 2 studies is difficult as the prior echocardiographic study examined 2.5 million SNPs in relation to LA diameter in meta‐analysis involving 5 cohorts. In the Framingham Heart Study, there may be further misclassification of LA size by conducting echocardiographic measurements in the anteroposterior diameter. M‐mode LA measurement has a poor correlation with LA volume determined by echocardiography.^[@b32]^

Atrial structural characteristics are likely modified by multiple clinical factors, eg, hypertension, left ventricular diastolic properties, and unrecognized AF. Our analysis did not include left ventricular diastolic function or other structural abnormalities that could influence LA diameter or volume. Our study is not able to examine the association of the AF SNPs and functional assessments such as the left atrial functional index or conduction as measured by P wave indices.

Our study has several important strengths. The Framingham Heart Study echocardiographic LA dimension and the CMR LA volume measurements were reproducible and conducted using standardized techniques. The SNPs selected for inclusion were identified from a series of large GWAS. However, we note that our study has multiple limitations. First, the Framingham Heart Study is primarily of European descent, limiting our ability to comment on the generalizability of our results to more diverse cohorts. Second, we used strict criteria in the selection of the AF‐related SNPs for association with LA dimensions. It is possible that other genetic loci associated with AF below stringent genome‐wide significance thresholds may be related to atrial structure. Third, we performed the assessments of LA size at a single time‐point. The AF associated SNPs may have a relation to longitudinal changes in LA structure that our analysis was not designed to assess. Consequently, we are not able to comment on the relation of the SNPs to longitudinal change that would distinguish atrial remodeling. Whether and how SNPs related to AF are related to trajectories or changes in LA dimensions remains an important question. Fourth, our echocardiography studies relied on M‐mode for determining LA dimension, potentially introducing systematic misclassification of the echocardiography measures. Fifth, 43% of participants included in the echocardiography cohort also participated in the AF GWAS. While the overlap in participants may have biased our results, Framingham participants were included as part of large consortia for determining the GWAS related to AF. Finally, our power calculation indicates that our sample size had limited statistical power. Our study would be enhanced by a far larger sample size.

In summary, our primary analysis did not identify a relation between SNPs associated with AF and LA structure in a community‐based study employing echocardiography and CMR for LA structural characterization. A secondary analysis excluding individuals with prevalent AF identified marginal associations. Further efforts in larger cohorts are indicated; demonstrating the relation between genetic exposures and changes in atrial structure and function may identify key intermediate steps in the pathogenesis of AF. Future studies that examine additional genetic loci, genomic expression, more diverse cohorts, and the association with longitudinal changes in atrial structure and function may more completely characterize atrial remodeling and its pathophysiologic relations with AF.
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